NEW YORK (GenomeWeb) – Thermo Fisher Scientific and French firm Cellectis have inked a series of agreements covering the use of TAL nucleases for a variety of applications.

Under the agreements, Thermo Fisher gains a worldwide license under Cellectis' IP rights to use TAL nucleases outside the therapeutics field with exclusive rights to grant sublicenses in research and development, bioproduction, and applied markets. Thermo Fisher's Life Technologies business markets TAL nucleases under the brand name TALEN for these applications.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.